Get startedLog in
    Picture of Bristol-Myers Squibb Co logo

    BMY — Bristol-Myers Squibb Co News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapSuper Stock
    All News

    Brief: Jiangsu Hengrui Pharmaceuticals Enters Collaboration And License Deals With Bristol-Myers Squibb

    Picture of Bristol-Myers Squibb Co logoBristol-Myers Squibb Co
    12/05/2026 05:17
    May 12 (Reuters) - Jiangsu Hengrui Pharmaceuticals Co Ltd 600276.SS:

ENTERING INTO COLLABORATION AND LICENSE AGREEMENTS WITH BRISTOL-MYERS SQUIBB

DEALS TO ADVANCE PORTFOLIO OF 13 EARLY STAGE PROGRAMS IN ONCOLOGY, HEMATOLOGY AND IMMUNOLOGY

BMS WILL PAY CO UP TO $950 MLN, INCLUDING $600 MLN UPFRONT PAYMENT

POTENTIAL TOTAL VALUE OF AGREEMENTS UP TO $15.2 BLN

Further company coverage: 600276.SS

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Bristol-Myers Squibb Co

    See all news